Shots:
- Boston will lead the development of selected programs through PoC. GSK gets an option to reacquire each program under pre-agreed terms for development and WW commercialization, after completion of POC studies
- If GSK exercises its repurchase option, Boston to receive a one-time payment and milestones along with royalties. If GSK selects not to reacquire a program, it will be eligible to receive milestones and royalties, meanwhile Boston will continue the development & commercialization of the programs
- The two programs include GSK3903371 and GSK3502421. The agreement follows companies’2018 collaboration for the acquisition of GSK’s 5 programs
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders first appeared on PharmaShots.
